Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^TM Platform, and StratX^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. 

Pulmonx^®, AeriSeal^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks and LungTraX^TM is a trademark of Pulmonx Corporation. 

Contact
Brian Johnston
Gilmartin Group
[email protected]

You May Also Be Interested In

• Bilibili Inc. Announces New $300 Million Share Repurchase Program
• Juniper Research Unveils Fintech & Payments Awards Winners for 2026
• LincNutri Introduces New Liposomal Glutathione Formula Tailored to Women’s Growing Demand for Antioxidant Wellness Support